Many microbes are extremophiles, capable of surviving conditions that would spell instant death for you and me. From deep-sea hydrothermal vents to boiling hot springs, these single-celled creatures have evolved special tools to help them thrive in tough places. Researchers have long wanted to harness these tools for human applications.
U.S. stocks edged back from their records as Wall Street counted down to a big jobs report that’s coming on Friday
U.S. donors gave $3.6 billion on Tuesday, an increase from the past two years, according to estimates from the nonprofit GivingTuesday
Lawmakers from states with legalized gambling are proposing standards for other states that are considering allowing internet betting
The average rate on a 30-year mortgage in the U.S. eased again this week, slipping to its lowest level since late October
ReNeuron has joined the long list of biotechs to leave London’s AIM stock market. The stem cell biotech is letting go of its listing after money troubles persuaded it to free itself from the costs and regulatory obligations of the exchange.
Shanghai Allist Pharmaceuticals has bought itself a starring role in China’s KRAS market, paying Jacobio Pharma 150 million Chinese yuan ($21 million) for rights to a near-approval inhibitor of the oncogene and a potentially complementary molecule.
NuCana has seen another of its reworked chemotherapies struggle to prove itself in the clinic, halving the biotech’s stock in post-market trading.
The FDA’s Center for Drug Evaluation and Research (CDER) is consolidating its artificial-intelligence-related activities under a single AI Council, in part in response to efforts from the Biden administration to ensure the safety and security of machine learning software.
In 2022, on the alpine shores of Lake Maggiore in northern Italy, longtime friends Samuel Bakhoum, M.D., Ph.D., and Stefano Santaguida, Ph.D., were catching up. Pandemic restrictions had prevented the two from seeing each other for years, but, at a small conference in the lakeside town of Stresa, they seized the opportunity to share what they’d been working on recently—the collapse of micronuclei in cancer cells.
Orion to use Aitia’s ‘digital twins’ to identity potential new cancer drugs
Windtree’s cardiogenic shock med raises blood pressure in latest phase 2 win
Merck’s Keytruda-LAG-3 combo fails to tame tough colorectal cancer in phase 3
New PicnicHealth service brings observational clinical trial research to the virtual world
OncoC4 founders take own science under their wing in new biotech merger
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain
Clinical trial site network Headlands Research opens new location in El Paso, Texas
NewHold Investment Corp. III Files to Offer Up to 20M Units in IPO
Lululemon longtime bear is still telling investors to sell the stock
